Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

Más betegség

• Renal or hepatic disease

Életkor

• Inability to provide informed consent (including individuals <18 years of age)

Egyéb

• Pregnancy or breastfeeding
• Current use of antibiotics or antibiotic use within the past month
• Current use of other probiotic, prebiotic, or synbiotic supplements
• Current use of iron and/or zinc supplements
• Change in the type of therapeutic regimen (pharmacotherapy) within the past three months
• Change in the dosage of the therapeutic regimen (pharmacotherapy) within the past month
• Insufficient understanding of the Greek language

• Crohn's disease: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
• Ulcerative colitis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
• Hypertension: Patients with systolic blood pressure of 130-139 mmHg or diastolic blood pressure of 80-89 mmHg, who maintain blood pressure within these ranges through lifestyle modifications, without active symptoms (e.g., headaches, dizziness), and not receiving antihypertensive medication.
• Anemia: Patients with hemoglobin <12 g/dL, serum iron <40 μg/dL, and ferritin <15 ng/mL for women, and hemoglobin <13 g/dL, serum iron <40 μg/dL, and ferritin <30 ng/mL for men. Absence of severe clinical consequences. Presence of fatigue, weakness, or dizziness, which is usually manageable.
• Multiple sclerosis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.